Showing 4081-4090 of 5771 results for "".
- Cognivue Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)https://modernod.com/news/cognivue-initiates-nationwide-clinical-study-to-assess-post-covid-19-syndrome-long-haul-syndrome/2479351/Neuroscience company Cognivue announced the initiation of
- Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officerhttps://modernod.com/news/outlook-therapeutics-appoints-c-russell-trenary-iii-as-president-and-chief-executive-officer/2479350/Outlook Therapeutics announced the appointment of C. Russell Trenary III as President, Chief Executive Officer and a member of the Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics’ President, CEO and CFO since June 2018, will continue serving as CFO and as a member o
- Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03https://modernod.com/news/bausch-lomb-completes-enrollment-of-second-phase-3-study-for-nov03/2479349/Bausch + Lomb and Novaliq announced the second of two phase 3 (MOJAVE) studies evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dy
- Phoenix, Knoxville, Kansas City Stand Out for Retinal Treatment Opportunity in the UShttps://modernod.com/news/phoenix-knoxville-kansas-city-stand-out-for-retinal-treatment-opportunity-in-the-us/2479346/The Phoenix metro area has the highest number of vitrectomies per provider in the US, while Knoxville, Tennessee, stands out for above average annual intravitreal injection volumes per provider. Kansas City is set apart by its high concentrations of high-volume IVT providers, according to Market
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for Phase 3 Trial of Zimura in GA Secondary to AMDhttps://modernod.com/news/iveric-bio-receives-fda-agreement-under-special-protocol-assessment-spa-for-phase-3-trial-of-zimura-in-ga-secondary-to-amd/2479341/Iveric bio announced that the company received written agreement from the FDA under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the company’s pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to a
- CVC Capital Partners VIII to Acquire Majority Stake in Raynerhttps://modernod.com/news/cvc-capital-partners-viii-to-invest-in-rayner/2479340/CVC Capital Partners VIII announced that it has agreed to acquire a majority interest in Rayner, the global ophthalmology business from UK-based private equity firm Phoenix Equity Partners. Terms of the deal were not disclosed. The transaction is expected to close in the third quar
- Nicox to Receive $2 Million from Ocumension as Milestone Payment Under Zerviate Agreementhttps://modernod.com/news/nicox-to-receive-2-million-from-ocumension-as-milestone-payment-under-zerviate-agreement/2479339/Nicox announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amend
- Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpointshttps://modernod.com/news/ocuphires-vega-1-phase-2-trial-in-presbyopia-meets-primary-and-secondary-endpoints/2479332/Ocuphire Pharma announced that the VEGA-1 phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move in
- Roche’s Actemra Gains FDA Emergency-Use in Hospitalized COVID-19 Patientshttps://modernod.com/news/roches-actemra-gains-fda-emergency-use-in-hospitalized-covid-19-patients/2479324/The FDA announced that it issued an emergency-use authorization (EUA) to Roche’s Actemra (tocilizumab) for the treatment of COVID-19 in hospitalized adults and paediatric patients, according to FirstWord. Specifically, the IL-6 receptor antagonist is cleared for use in people who are receiv